Viridian Therapeutics, Inc. (FRA:1S1)

Germany · Delayed Price · Currency is EUR

23.59

+0.17 (0.73%)

Last updated: Feb 20, 2026, 8:00 AM CET

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
Discovering, Developing and Commercializing Potential Best-In-Class Medicines for Serious and Rare Diseases	302.00K	314.00K	1.77M	2.96M	1.05M
Discovering, Developing and Commercializing Potential Best-In-Class Medicines for Serious and Rare Diseases Growth	-3.82%	-82.28%	-40.20%	182.19%	-76.46%
Total	302.00K	314.00K	1.77M	2.96M	1.05M
Total Growth	-3.82%	-82.28%	-40.20%	182.19%	-76.46%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
United States	302.00K	314.00K	1.77M	2.96M	1.05M
United States Growth	-3.82%	-82.28%	-40.20%	182.19%	-76.46%
Total	302.00K	314.00K	1.77M	2.96M	1.05M
Total Growth	-3.82%	-82.28%	-40.20%	182.19%	-76.46%

Source: S&P Global Market Intelligence.